Excipients are carrier agents beneficial for biopharmaceutical formulations. They offer efficient binding of ingredients, increase drug stability in the dosage form and modify the solubility of API. Excipients are inert, reproducible substances created from minerals, sugar, wheat, corn, and other such ingredients. They can reduce operating costs, enhance productivity, and improve product quality. The Global Biopharmaceutical Excipient Manufacturing Market is valued at US$ 1156.5 Mn in 2021, and it is expected to reach US$ 2624.3 Mn by 2030, with a CAGR of 9.7 % during a forecast period of 2022-2030.
Major driving factors of the biopharmaceutical excipient manufacturing market are the surging applications of excipients, increasing initiatives by market players to develop excipients for innovating high-quality drugs, growing focus on the development of novel drugs, rising cases of chronic diseases, increasing use of lipid and sucrose-based excipients, advances in the field of pharmaceutical manufacturing, and the increasing R&D activities in the pharmaceutical industries. The increasing COVID cases have increased the drug manufacturing burden of biopharmaceutical companies to treat the affected patients. Hence, companies are rising their focus on fast drug development. Excipients are effective and efficient in enhancing the manufacturing process for biopharmaceuticals. Therefore, the demand for biopharmaceutical excipients is surging to develop innovative and stabilized drugs, thereby creating significant growth opportunities during the forecast period. However, complexities associated with drug manufacturing along with the requirement of high capital investments may hinder the market growth during the forecast period.
The biopharmaceutical excipient manufacturing market is segmented based on the type of biologics, excipient types, scale of operation, and region. The type of biologics segment comprises antibodies, vaccines, cell therapies, and other biologics. The market is categorized into carbohydrates, polymers, solubilizers/surfactants, polyols, proteins/amino acids, and others in terms of excipient types. The carbohydrates segment is expected to dominate this market in the forthcoming years due to the rising use of carbohydrate-based excipient products such as sucrose and starch in drug formulations. By scale of operation, the market is classified into preclinical, clinical, and commercial. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Asia-Pacific is estimated to be the rapidly growing regional market in the next few years due to the increasing incidences of chronic diseases, rising government funding for healthcare, and the growing demand for drugs. India and China are the emerging countries of this market
Some of the key players operating in the biopharmaceutical excipient manufacturing market are ABITEC (US), Avantor (US), BASF Pharma (Germany), Corden Pharma (Germany), DFE Pharma (Germany), Evonik (Germany), Kirsch Pharma (Germany), Merck KGaA (Germany), Pfanstiehl (US), Roquette (France), Spectrum Chemical Manufacturing (US), SPI Pharma (US), and Others.